Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.12 USD

1.12
2,306,350

+0.05 (4.67%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $1.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals

by Zacks Equity Research

Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More

by Zacks Equity Research

Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.

Zacks Equity Research

Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

by Zacks Equity Research

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 18.75% and 680.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 11.76% and -99.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Lexicon Pharmaceuticals (LXRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 82.14% and 15.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

by Zacks Equity Research

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

Zacks Equity Research

Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

Zacks Equity Research

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

Zacks Equity Research

Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

by Zacks Equity Research

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

Zacks Equity Research

Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.

Zacks Equity Research

Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit

by Zacks Equity Research

Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.

Zacks Equity Research

What's in the Offing for Hewlett Packard (HPE) Q1 Earnings?

by Zacks Equity Research

Hewlett Packard's (HPE) Q1 performance likely to have benefited from higher demand for its cloud services on the ongoing digital transformation and improved supply-chain execution.

Zacks Equity Research

Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus

by Zacks Equity Research

Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.

Zacks Equity Research

Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

Zacks Equity Research

Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates

by Zacks Equity Research

Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.

Zacks Equity Research

Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues

by Zacks Equity Research

Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

Zacks Equity Research

Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) reports no revenues for the fourth quarter of 2020.

Zacks Equity Research

Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.

Zacks Equity Research

ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.

Zacks Equity Research

Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright

by Zacks Equity Research

Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations. Stock up.